Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors
NCT06546150Phase 1Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2024
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RE002 T cell in solid tumor, sponsored by Henan Cancer Hospital. Primary endpoint: Overall Response Rate. Started Mar 2024; status: recruiting.
02
Drugs
RE002 T cell
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06546150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06546150.